Authors: Lakeem Rose/Kate White 

Five years ago, hardly anyone was talking about GLP‑1. 

In 2026, it feels like everyone is taking Ozempic. 

GLP‑1 receptor agonists have become the most discussed drug class in the world. They are celebrated for dramatic weight‑loss results, criticized for their influence on cultural beauty standards, blamed for repeated supply shortages of diabetes medications, and surrounded by almost constant industry speculation. 

Lost in that conversation is what GLP‑1s were originally developed to do. Long before they became weight‑loss sensations, these drugs were designed as metabolic regulators, aimed at improving insulin secretion and glycemic control. As the market matures, attention is shifting toward a more structural challenge: the foundational patents that underpin today’s GLP‑1 therapies are approaching expiration. 

Clinical trial activity offers a clear view into how companies are responding, and increasingly, those signals are emerging from China. 

This article draws on findings from Patsnap’s 2026 GLP1-R Market Landscape Report, which maps the full patent and clinical trial landscape shaping the next phase of the category.  

The GLP‑1 Market Is Hitting a Patent Wall 

Many of the earliest GLP‑1 patents were filed long before the drugs reached their current commercial prominence. The cliff is no longer theoretical. Liraglutide’s core US patent expired in 2024/2025, with generics already on the market. Semaglutide’s key patent expired in China and India in early 2026 triggering an immediate wave of generic competition.

In the US, semaglutide’s core patent holds until 2032, but layered portfolios for some molecules extend protections all the way to 2045. The pattern is familiar in pharma: a drug generates enormous returns, competitors pile in, and exclusivity eventually erodes. What makes GLP-1 different is the speed and scale. These drugs became cultural phenomena before the patent cycle had time to play out quietly. Now the whole industry is watching the clock.  

For companies with billion-dollar GLP-1 platforms, the response can’t just be incremental. Modest changes to dosing schedules or delivery formats buy time, but they don’t rebuild the moat protecting their work.  

Sustained advantage requires new IP that remains defensible even as first-generation patents fall away. Our GLP-1 Market Report identifies three strategies companies are pursuing to get there:  

• New indications: expanding into cardiometabolic, liver, and kidney disease to establish differentiated clinical claims beyond obesity  

• New formulations and delivery routes: oral small molecules, long-acting injectables, and lower frequency dosing 

• New molecular architectures: multi-agonists, biologic hybrids, and next generation constructs that move beyond first-generation scaffolds entirely  

Clinical Trials Reveal Where Companies Are Creating New IP 

Clinical trials are among the most expensive and time‑intensive decisions a drug developer can make. They are not exploratory bets. Trial design, location, and scope reflect where companies believe durable value can still be created. For that reason, clinical trial activity offers one of the clearest signals of long‑term intent.  

China sits at nearly the same trial volume as the US, despite having a lower obesity rate. This isn’t an anomaly. 

The small molecule space illustrates this most clearly. AstraZeneca paid $185 million upfront to license ECC5004 out of China, recognizing that some of the most compelling next‑generation GLP‑1R science is originating there. Amgen brought MariTide into China specifically to pursue a first‑in‑class position. Semaglutide’s patent expiry in China in 2026 accelerated all of this: with at least 17 generic semaglutide candidates already in Phase 3 trials ahead of that date, the market moved fast, and the companies investing in differentiated next‑generation assets are now positioning for what comes after the generic wave. 

China offers scale, speed, and a regulatory environment that has been actively streamlined to support novel therapeutic mechanisms. For companies stress‑testing next‑generation GLP‑1R concepts, that combination is hard to replicate elsewhere. Its importance lies less in what conditions are being treated today, and more in what kinds of assets companies are racing to build for tomorrow. 

Conclusion: The Next GLP‑1 Winners Will Be the Best IP Architects 

Obesity and diabetes remain enormous commercial battlegrounds, and competition is not slowing down. But as exclusivity erodes, and generics enter major markets, the drugs that command premium pricing based on novelty alone will face a different competitive reality. Success will depend on who built platforms, not just products.  

That distinction matters. A product is defensible for as long as its patents hold. A platform generates new IP continuously, through new indications, new delivery formats, and new molecular designs that each carry their own exclusivity. The companies that understood this early enough are already acting on it: global players are increasingly licensing innovation that originated in China, bringing it into their portfolios precisely because some of the most compelling next‑generation GLP‑1R science is now coming from there. That’s a structural shift in where the category frontier sits. 

The clinical trial data makes the intent visible. Where companies invest in trials, they are signaling where they believe the next defensible advantages can be created. By that measure, the next decade of GLP‑1 innovation has already started, and the map of where it’s happening is clearer than most people realize. 

Want the full picture? Our Small Molecule GLP‑1R Agonists Market Landscape report covers the complete patent expiry timeline, clinical trial breakdowns by country and indication, and the next‑generation molecular architectures reshaping the category. 

FAQ